☆ 4.6 Letter

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

BLOOD ADVANCES (2022)

Get Full Text
Add to Collection

Journal

BLOOD ADVANCES
Volume 6, Issue 16, Pages 4816-4820

Publisher

ELSEVIER
DOI: 10.1182/bloodadvances.2021006193

Keywords

-

Categories

Hematology

Funding

  1. Novartis Pharmaceuticals

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.